What does aducanumab treatment of Alzheimer's disease mean for research on vascular cognitive disorders?

Authors :: Wallin A
Alladi S
Black SE
Chen C
Greenberg SM
Gustafson D
Isaacs JD
Jokinen H
Kalaria R
Mok V
Pantoni L
Pasquier F
Roman GC
Rosenberg GA
Schmidt R
Smith EE
Hainsworth AH
Source :: Cerebral circulation - cognition and behavior [Cereb Circ Cogn Behav] 2022 Feb 11; Vol. 3, pp. 100044. Date of Electronic Publication: 2022 Feb 11 (Print Publication: 2022).
Publication Year :: 2022
Abstract: •Controversial registration of aducanumab for Alzheimer's Disease•Aducanumab is the subject of post-licensing observational studies aiming to follow the effects of the drug•Given the high prevalence of cerebrovascular pathology it is important that these studies do not ignore vascular cognitive disorders•The studies may give detailed phenotyping data that may lead to knowledge of targets for treatments of patients with vascular cognitive disorders.<br /> (© 2022 Published by Elsevier B.V.)

Full Text Access

Tools